| Nome |
# |
|
I tumori stromali gastrointestinali: dalla biologia alla clinica, file e3ad8916-9ee0-da0e-e053-3705fe0a2b96
|
1.254
|
|
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?, file e3ad891d-4881-da0e-e053-3705fe0a2b96
|
548
|
|
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis, file e3ad891c-7bb9-da0e-e053-3705fe0a2b96
|
522
|
|
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives, file e3ad8921-94d5-da0e-e053-3705fe0a2b96
|
256
|
|
Liquid Biopsy in Breast Cancer, file e3ad891b-6794-da0e-e053-3705fe0a2b96
|
253
|
|
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials, file e3ad8921-8325-da0e-e053-3705fe0a2b96
|
242
|
|
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and
biomolecular features, file e3ad8915-d0cc-da0e-e053-3705fe0a2b96
|
221
|
|
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma, file e3ad891e-ce83-da0e-e053-3705fe0a2b96
|
216
|
|
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients, file e3ad891e-ce8b-da0e-e053-3705fe0a2b96
|
201
|
|
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions, file e3ad8923-2872-da0e-e053-3705fe0a2b96
|
195
|
|
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials, file e3ad891f-81a2-da0e-e053-3705fe0a2b96
|
192
|
|
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis, file e3ad891f-ce1c-da0e-e053-3705fe0a2b96
|
191
|
|
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus, file e3ad8919-b53d-da0e-e053-3705fe0a2b96
|
186
|
|
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients, file e3ad891f-0eff-da0e-e053-3705fe0a2b96
|
182
|
|
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma, file e3ad8919-9cf9-da0e-e053-3705fe0a2b96
|
177
|
|
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice, file e3ad891c-cca3-da0e-e053-3705fe0a2b96
|
170
|
|
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC), file e3ad8921-474a-da0e-e053-3705fe0a2b96
|
156
|
|
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients, file e3ad8925-51cb-da0e-e053-3705fe0a2b96
|
155
|
|
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma, file e3ad8916-2d00-da0e-e053-3705fe0a2b96
|
147
|
|
Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the exon, file e3ad8927-2701-da0e-e053-3705fe0a2b96
|
147
|
|
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis, file e3ad8920-2855-da0e-e053-3705fe0a2b96
|
137
|
|
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?, file e3ad8920-902b-da0e-e053-3705fe0a2b96
|
113
|
|
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives, file e3ad8922-f67f-da0e-e053-3705fe0a2b96
|
113
|
|
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies, file e3ad8928-e0fa-da0e-e053-3705fe0a2b96
|
113
|
|
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2, file e3ad8922-ee6c-da0e-e053-3705fe0a2b96
|
107
|
|
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome, file e3ad8927-7bb5-da0e-e053-3705fe0a2b96
|
104
|
|
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway, file e3ad8919-4bd3-da0e-e053-3705fe0a2b96
|
98
|
|
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1, file e3ad8921-ef20-da0e-e053-3705fe0a2b96
|
88
|
|
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes, file e3ad8922-de27-da0e-e053-3705fe0a2b96
|
87
|
|
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib, file e3ad8922-e923-da0e-e053-3705fe0a2b96
|
86
|
|
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge, file e3ad8927-342f-da0e-e053-3705fe0a2b96
|
85
|
|
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy (Supportive Care in Cancer, (2019), 27, 9, (3593-3597), 10.1007/s00520-019-4645-3), file e3ad8921-fd85-da0e-e053-3705fe0a2b96
|
81
|
|
Recent advances in desmoid tumor therapy, file e3ad8922-e43e-da0e-e053-3705fe0a2b96
|
81
|
|
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming, file e3ad8925-4d86-da0e-e053-3705fe0a2b96
|
73
|
|
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis, file e3ad8923-0181-da0e-e053-3705fe0a2b96
|
69
|
|
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors, file e3ad8923-0184-da0e-e053-3705fe0a2b96
|
68
|
|
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer, file e3ad8917-15e1-da0e-e053-3705fe0a2b96
|
66
|
|
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?, file e3ad891b-5ebe-da0e-e053-3705fe0a2b96
|
57
|
|
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma, file e3ad8926-e916-da0e-e053-3705fe0a2b96
|
56
|
|
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone., file e3ad891d-96f4-da0e-e053-3705fe0a2b96
|
55
|
|
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab, file e3ad891c-2d18-da0e-e053-3705fe0a2b96
|
46
|
|
Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study, file e3ad8927-b960-da0e-e053-3705fe0a2b96
|
44
|
|
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible, file b7ea5aad-4f2d-45b8-a0e9-b5e45cdf82c1
|
39
|
|
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs), file e3ad8927-33ba-da0e-e053-3705fe0a2b96
|
36
|
|
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis, file bde11d1e-a3c7-4772-a073-473b4c78c72c
|
33
|
|
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers, file e3ad891a-81b7-da0e-e053-3705fe0a2b96
|
32
|
|
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases., file e3ad8915-eeb6-da0e-e053-3705fe0a2b96
|
28
|
|
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study, file 1606f643-b66b-4e9f-96d7-5908f5d2d3de
|
25
|
|
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement, file e3ad8928-01f6-da0e-e053-3705fe0a2b96
|
24
|
|
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma, file 384c0206-a63b-49f3-8473-624f7ef38a26
|
22
|
|
Higher Incidence of Cancer Therapy-Related Cardiac Dysfunction in the COVID-19 Era: A Single Cardio-Oncology Center Experience, file 010b7945-2371-40e8-960a-209248121017
|
18
|
|
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival?, file e3ad8927-4bd6-da0e-e053-3705fe0a2b96
|
18
|
|
null, file e3ad8917-11b6-da0e-e053-3705fe0a2b96
|
16
|
|
Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women, file e3ad8927-a7e8-da0e-e053-3705fe0a2b96
|
15
|
|
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway, file e3ad8924-a00f-da0e-e053-3705fe0a2b96
|
14
|
|
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay, file 1bd24d10-3d45-4e73-a4c4-698c69ce8bbb
|
13
|
|
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints, file cd7a0e37-141f-45ab-9caa-19d414fdddfd
|
13
|
|
Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: A new prognostic factor?, file e3ad8928-a0d9-da0e-e053-3705fe0a2b96
|
13
|
|
Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography, file e3ad8928-d87d-da0e-e053-3705fe0a2b96
|
12
|
|
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients, file e3ad8920-b57b-da0e-e053-3705fe0a2b96
|
11
|
|
The molecular tumor board: a tool for the governance of precision oncology in the real world, file e3ad8928-9ecb-da0e-e053-3705fe0a2b96
|
11
|
|
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma, file e3ad891e-62bc-da0e-e053-3705fe0a2b96
|
9
|
|
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM), file e3ad8928-9ec9-da0e-e053-3705fe0a2b96
|
9
|
|
Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report, file e3ad891a-0ad8-da0e-e053-3705fe0a2b96
|
8
|
|
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies, file e3ad8928-c20c-da0e-e053-3705fe0a2b96
|
8
|
|
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors, file e1ff73b9-70c2-4089-bba2-b453fe3437b1
|
6
|
|
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients?, file e3ad891f-7c6d-da0e-e053-3705fe0a2b96
|
6
|
|
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial, file e3ad8926-611b-da0e-e053-3705fe0a2b96
|
6
|
|
Healthcare Professional Communication on Sexual Health: A Report from the Italian Working Group on Adolescents and Young Adults with Cancer, file 1a974e50-9a1c-47af-9c3f-9a09aaf0bde1
|
5
|
|
Liquid Biopsy in Gastrointestinal Stromal Tumor, file e3ad891c-6d78-da0e-e053-3705fe0a2b96
|
5
|
|
Tumor markers in urogynaecological tumors., file e3ad891e-d645-da0e-e053-3705fe0a2b96
|
4
|
|
Network approach in liquidomics landscape, file 67a2d289-11ac-48bc-9699-cb58bdc676bb
|
3
|
|
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections, file 7444d3a2-b0ae-4c9a-9594-3beae629cb66
|
3
|
|
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors, file e3ad891a-bd84-da0e-e053-3705fe0a2b96
|
3
|
|
Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors, file e3ad8927-1ea6-da0e-e053-3705fe0a2b96
|
3
|
|
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab, file 06c2c8e0-8887-451c-b39a-83a92c787a67
|
2
|
|
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study, file 5bcfcd30-ad66-4a32-9917-8b67260bf7b8
|
2
|
|
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?, file 93dd8302-8d55-40c0-8fb8-6ec6c2c217c7
|
2
|
|
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies, file 9b23f50e-2ea2-4634-b349-e0309a670ef1
|
2
|
|
Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices, file 9de4b735-c0e8-4b33-a63c-e081d49c907f
|
2
|
|
A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST), file af63fcb3-3a7d-4ba7-83c1-c55be1d05027
|
2
|
|
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential, file e3ad891d-b5e9-da0e-e053-3705fe0a2b96
|
2
|
|
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review, file e3ad891e-6582-da0e-e053-3705fe0a2b96
|
2
|
|
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?, file e3ad8924-cf47-da0e-e053-3705fe0a2b96
|
2
|
|
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis, file efa9285f-dd64-4765-9f55-8e1cae446f64
|
2
|
|
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study, file fbf463d7-c318-4e73-a067-6692011445a3
|
2
|
|
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study, file 34a48822-d953-447b-8978-d27fe595b136
|
1
|
|
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies, file 4b3d12d8-cb0a-4674-a92c-83675b957c0d
|
1
|
|
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study, file c0aaf102-a7b8-4313-b9f9-1862e7df1ebb
|
1
|
|
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1), file e0dd8118-50dd-45fe-b018-754b1af495c3
|
1
|
|
Serum follistatin in patients with prostate cancer metastatic to the bone, file e3ad8915-b148-da0e-e053-3705fe0a2b96
|
1
|
|
Liquid Biopsy in Gynecological Cancers, file e3ad891b-2c92-da0e-e053-3705fe0a2b96
|
1
|
|
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin, file e3ad8921-f78a-da0e-e053-3705fe0a2b96
|
1
|
|
Body mass index as a risk factor for toxicities in patients with advanced soft-tissue sarcoma treated with trabectedin, file e3ad8923-2c91-da0e-e053-3705fe0a2b96
|
1
|
|
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors, file e3ad8927-05b6-da0e-e053-3705fe0a2b96
|
1
|
|
Cancer of the Thyroid, file e3ad8927-4776-da0e-e053-3705fe0a2b96
|
1
|
|
Current treatment options for HER2-positive breast cancer patients with brain metastases, file e3ad8928-a0d8-da0e-e053-3705fe0a2b96
|
1
|
|
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies, file e3ad8928-aacd-da0e-e053-3705fe0a2b96
|
1
|
|
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors, file e3ad8928-afd4-da0e-e053-3705fe0a2b96
|
1
|
|
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison, file e3ad8928-bc22-da0e-e053-3705fe0a2b96
|
1
|
| Totale |
7.945 |